Keywords: Computed Tomography, Emission Computed, Radiotherapy, Antineoplastic Agent, Fluorodeoxyglucose F 18, Breast Cancer, Cancer Radiotherapy, Cancer Relapse, Cancer Staging, Colorectal Cancer, Computer Assisted Emission Tomography, Diagnostic Accuracy, Disease Course, Esophagus Carcinoma, Gynecologic Cancer, Head And Neck Cancer, Human, Larynx Cancer, Lung Cancer, Lung Metastasis, Lung Non Small Cell Cancer, Lymphoma, Methodology, Nonhodgkin Lymphoma, Patient Selection, Radiation Dose, Radiation Sickness, Review, Seminoma, Squamous Cell Carcinoma, Stomach Carcinoma, Treatment Planning, Tumor Volume, Physician, S Practice Patterns, Positron-Emission Tomography, Practice Guidelines, Radiotherapy Planning, Computer-Assisted, Subtraction Technique, X-Ray Computed, Radioisotope, Cobalt, Cancer Surgery, Cobalt Therapy, Larynx Carcinoma, Article, Glottis, Larynx Tumor, Lymph Node Metastasis, Postoperative Care, Cobalt Radioisotopes, English Abstract, Laryngeal Neoplasms, Lymphatic Metastasis, Radiotherapy Dosage, Cobalt Radioisotopes Therapeutic Use, Laryngeal Neoplasms Radiotherapy, Postoperative Care Methods,
Affiliations: Center of Molecular Bioimaging, University of Milano-Bicocca, Milan, Italy
Institute of Molecular Bioimaging and Physiology (IBFM), CNR, Milan, Italy
Department of Nuclear Medicine, H. S. Gerardo, Via Pergolesi 33, 20052 Monza, Italy
Department of Radiation Oncology, San Raffaele Scientific Institute, Milan, Italy
Div. Radioter., Ist. Studio Cura Tum., 80131 Napoli, Italy
References: Not available.
PET/CT and radiotherapy
This article reviews the state of the art of PET/CT applications in radiotherapy, specifically its use in disease staging, patient selection, treatment planning and treatment evaluation. Diseases for which radiotherapy with radical intent is indicated will be considered, as well as those in which PET/CT may actually change the course of disease. The methodological and technological aspects of PET/CT in radiotherapy are discussed, focusing on the problem of target volume definition with CT and PET functional imaging and the problem of tumor motion with respect to imaging and dose delivery.
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(418 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote
Ntziachristos V, Cuénod CA, Fournier L, Balvay D, Pradel C, Siauve N, Clement O, Jouannot E, Lucidarme O, Vecchio SD, Salvatore M, Law B, Tung C-H, Jain RK, Fukumura D, Munn LL, Brown EB, Schellenberger E, Montet X, Weissleder R, Clerck ND, Postnov A * Tumor Imaging(446 views) Textbook Of In Vivo Imaging In Vertebrates (ISSN: 9780-4700), 2007 Jul 16; 1: 277-309. Impact Factor:1.148 ViewExport to BibTeXExport to EndNote